Ezetimibe / Atorvastatin Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10/10 mg, 10/20 mg, 10/40 mg, 10/80 mg

Reference Brands: Liptruzet (USA), Atozet (EU), Aztor EZ (India)

Category: Heart Disorder

Ezetimibe/Atorvastatin is a combination medication used to lower cholesterol levels in patients with hyperlipidemia. It works by reducing the absorption of cholesterol in the intestine (Ezetimibe) and inhibiting cholesterol synthesis in the liver (Atorvastatin). This dual action helps decrease LDL cholesterol and triglycerides while increasing HDL cholesterol. Ezetimibe / Atorvastatin is available in Tablets and strengths such as 10/10 mg, 10/20 mg, 10/40 mg, 10/80 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Ezetimibe / Atorvastatin is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Ezetimibe / Atorvastatin can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Ezetimibe / Atorvastatin is a combination medication used for the management of hypercholesterolemia and other lipid disorders. It combines two complementary mechanisms to effectively reduce cholesterol levels in the body. Ezetimibe belongs to a class of selective cholesterol-absorption inhibitors that works by blocking the absorption of cholesterol from the small intestine, while atorvastatin is a statin that reduces cholesterol production in the liver by inhibiting the HMG-CoA reductase enzyme.

This combination therapy is indicated for patients with primary hyperlipidemia, mixed dyslipidemia, and familial hypercholesterolemia who require additional cholesterol reduction beyond lifestyle changes or single-agent therapy. By lowering total cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein B (ApoB), and non-high-density lipoprotein (non-HDL) cholesterol, the medication helps reduce the risk of cardiovascular diseases such as heart attack and stroke.

The combination of ezetimibe and atorvastatin provides a dual approach to lipid management by both decreasing cholesterol absorption and reducing its synthesis in the liver. This makes it a valuable treatment option for patients who need more aggressive cholesterol control. Proper medical supervision and regular lipid monitoring are recommended to ensure safe and effective therapy.